Pular para o conteúdo
Merck

Pseudohalide anions reveal a novel extracellular site for potentiators to increase CFTR function.

British journal of pharmacology (2012-05-23)
Man-Song Li, Elizabeth A Cowley, Paul Linsdell
RESUMO

There is great interest in the development of potentiator drugs to increase the activity of the cystic fibrosis transmembrane conductance regulator (CFTR) in cystic fibrosis. We tested the ability of several anions to potentiate CFTR activity by a novel mechanism. Patch clamp recordings were used to investigate the ability of extracellular pseudohalide anions (Co(CN)(6) (3-) , Co(NO(2) )(6) (3-) , Fe(CN)(6) (3-) , IrCl(6) (3-) , Fe(CN)(6) (4-) ) to increase the macroscopic conductance of mutant CFTR in intact cells via interactions with cytoplasmic blocking anions. Mutagenesis of CFTR was used to identify a possible molecular mechanism of action. Transepithelial short-circuit current recordings from human airway epithelial cells were used to determine effects on net anion secretion. Extracellular pseudohalide anions were able to increase CFTR conductance in intact cells, as well as increase anion secretion in airway epithelial cells. This effect appears to reflect the interaction of these substances with a site on the extracellular face of the CFTR protein. Our results identify pseudohalide anions as increasing CFTR function by a previously undescribed molecular mechanism that involves an interaction with an extracellular site on the CFTR protein. Future drugs could utilize this mechanism to increase CFTR activity in cystic fibrosis, possibly in conjunction with known intracellularly-active potentiators.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Sodium hexanitrocobaltate(III), ACS reagent
Sigma-Aldrich
Sodium hexanitrocobaltate(III), puriss. p.a., for the determination of K, ACS reagent
Sigma-Aldrich
Potassium hexachloroiridate(IV), 99.99% trace metals basis
Sigma-Aldrich
Potassium hexachloroiridate(IV), technical grade